Transition from LDL apheresis to evolocumab in heterozygous FH is equally effective in lowering LDL, without lowering HDL cholesterol

Atherosclerosis

Volumn 251, Issue , 2016, Pages 119-123

  Lappegård, Knut Tore ^a,b   Enebakk, Terje ^a   Thunhaug, Hilde ^a   Hovland, Anders ^a,b  

^a NORDLAND HOSPITAL   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

Author keywords

Familial hypercholesterolemia; LDL apheresis; PCSK9 inhibitors

Indexed keywords

EVOLOCUMAB; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; HYPOCHOLESTEROLEMIC AGENT; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9;

APHERESIS; ARTICLE; CASE REPORT; COMPARATIVE EFFECTIVENESS; CORONARY ARTERY DISEASE; DRUG SAFETY; FAMILIAL HYPERCHOLESTEROLEMIA; HEALTH STATUS; HUMAN; LIPOPROTEIN APHERESIS; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; ANGIOGRAPHY; ANTAGONISTS AND INHIBITORS; BLOOD; COMPLICATION; FEMALE; HETEROZYGOTE; MALE; METABOLISM; MIDDLE AGED; MUTATION; TREATMENT OUTCOME;

ANGIOGRAPHY; ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; BLOOD COMPONENT REMOVAL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; FEMALE; HETEROZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; MUTATION; PROPROTEIN CONVERTASE 9; QUALITY OF LIFE; TREATMENT OUTCOME;

EID: 84974839240     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2016.06.015     Document Type: Article

References (33)

1. Gidding S.S., Champagne M.A., de Ferranti S.D., et al. The agenda for familial hypercholesterolemia a scientific statement from the american heart association. Circulation 2015, 132:2167-2192. 10.1161/CIR.0000000000000297.
2. Pedersen T.R. The success story of LDL cholesterol lowering. Circ. Res. 2016, 118:721-731. 10.1161/CIRCRESAHA.115.306297.
3. Stroes E.S., Thompson P.D., Corsini A., et al. Statin-associated muscle symptoms: impact on statin therapy-European atherosclerosis society consensus panel statement on assessment, aetiology and management. Eur. Heart J. 2015, 36:1012-1022. 10.1093/eurheartj/ehv043.
4. Moriarty P.M., Hemphill L. Lipoprotein apheresis. Endocrinol. Metab. Clin. North Am. 2016, 45:39-54. 10.1016/j.ecl.2015.09.003.
5. Hovland A., Marcovina S., Hardersen R., Enebakk T., Mollnes T.E., Lappegård K.T. Three different LDL apheresis columns efficiently and equally reduce lipoprotein(a) concentrations in patients with familial hypercholesterolemia and small apolipoprotein(a) particles. Transfus. Apher. Sci. 2012, 46:73-76. 10.1016/j.transci.2011.11.016.
6. Alonso R., Andres E., Mata N., et al. Lipoprotein(a) levels in familial hypercholesterolemia: an important predictor of cardiovascular disease independent of the type of LDL receptor mutation. J. Am. Coll. Cardiol. 2014, 63:1982-1989. 10.1016/j.jacc.2014.01.063.
7. Lappegård K.T., Hovland A. Side effects in low-density lipoprotein apheresis - types, frequency and clinical relevance. Clin. Lipidol. 2011, 6:717-722. 10.2217/CLP.11.52.
8. Stefanutti C., Thompson G.R. Lipoprotein apheresis in the management of familial hypercholesterolaemia: historical perspective and recent advances. Curr. Atheroscler. Rep. 2015, 17:465. 10.1007/s11883-014-0465-6.
9. Shimada Y.J., Cannon C.P. PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future. Eur. Heart J. 2015, 36:2415-2424. 10.1093/eurheartj/ehv174.
10. Tavori H., Rashid S., Fazio S. On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects. Atherosclerosis 2015, 238:264-270. 10.1016/j.atherosclerosis.2014.12.017.
11. Banerjee Y., Santos R.D., Al-Rasadi K., Rizzo M. Targeting PCSK9 for therapeutic gains: have we addressed all the concerns?. Atherosclerosis 2016, 248:62-75. 10.1016/j.atherosclerosis.2016.02.018.
12. Robinson J.G., Farnier M., Krempf M., et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 2015, 372:1489-1499. 10.1056/NEJMoa1501031.
13. Sabatine M.S., Giugliano R.P., Wiviott S.D., et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N. Engl. J. Med. 2015, 372:1500-1509. 10.1056/NEJMoa1500858.
14. EuroQol Group EuroQol-a new facility for the measurement of health-related quality of life. Health Policy 1990, 16:199-208.
15. Hovland A., Hardersen R., Sexton J., Mollnes T.E., Lappegård K.T. Different inflammatory responses induced by three LDL-lowering apheresis columns. J. Clin. Apher. 2009, 24:247-253. 10.1002/jca.20223.
16. Thompson G.R., Barbir M., Davies D., et al. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis 2010, 208:317-321. 10.1016/j.atherosclerosis.2009.06.010.
17. Chan J.C., Piper D.E., Cao Q., et al. A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:9820-9825. 10.1073/pnas.0903849106.
18. Koren M.J., Giugliano R.P., Raal F.J., et al. Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-Week results from the open-label study of long-term evaluation against LDL-C (OSLER) randomized trial. Circulation 2014, 129:234-243. 10.1161/CIRCULATIONAHA.113.007012.
19. Raal F., Scott R., Somaratne R., et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD) randomized trial. Circulation 2012, 10.1161/CIRCULATIONAHA.112.144055.
20. Guerin M. Reverse cholesterol transport in familial hypercholesterolemia. Curr. Opin. Lipidol. 2012, 23:377-385. 10.1097/MOL.0b013e328353ef07.
21. Santos-Gallego C.G. HDL: quality or quantity?. Atherosclerosis 2015, 243:121-123. 10.1016/j.atherosclerosis.2015.08.027.
22. Santos-Gallego C.G., Giannarelli C., Badimón J.J. Experimental models for the investigation of high-density lipoprotein-mediated cholesterol efflux. Curr. Atheroscler. Rep. 2011, 3:266-276. 10.1007/s11883-011-0177-0.
23. Khera A.V., Everett B.M., Caulfield M.P., et al. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin). Circulation 2014, 129:635-642. 10.1161/CIRCULATIONAHA.113.004406.
24. Jaeger B.R., Richter Y., Nagel D., et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat. Clin. Pract. Cardiovasc Med. 2009, 6:229-239. 10.1038/ncpcardio1456.
25. Waldmann E., Parhofer K.G. Lipoprotein apheresis to treat elevated lipoprotein (a). J. Lipid Res. 2016, jlr-R056549.
26. Lipinski M.J., Benedetto U., Escarcega R.O., et al. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. Eur. Heart J. 2016, 37:536-545. 10.1093/eurheartj/ehv563.
27. Thompson G.R. LDL apheresis. Atherosclerosis 2003, 167:1-13.
28. Hoover-Plow J., Huang M. Lipoprotein(a) metabolism: potential sites for therapeutic targets. Metabolism 2013, 62:479-491. 10.1016/j.metabol.2012.07.024.
29. Hovland A., Hardersen R., Mollnes T.E., Lappegård K.T. Selective whole blood lipoprotein apheresis to prevent pancreatitis in drug refractory hypertriglyceridemia. JOP 2010, 11:467-469.
30. Nordestgaard B.G., Benn M., Schnohr P., Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007, 298:299-308. 10.1001/jama.298.3.299.
31. Langsted A., Freiberg J.J., Tybjaerg-Hansen A., Schnohr P., Jensen G.B., Nordestgaard B.G. Nonfasting cholesterol and triglycerides and association with risk of myocardial infarction and total mortality: the Copenhagen City Heart Study with 31 years of follow-up. J. Intern. Med. 2011, 270:65-75. 10.1111/j.1365-2796.2010.02333.x.
32. Libby P. Triglycerides on the rise: should we swap seats on the seesaw?. Eur. Heart J. 2015, 36:774-776. 10.1093/eurheartj/ehu500.
33. Reiner Ž. Management of patients with familial hypercholesterolaemia. Nat. Rev. Cardiol. 2015, 10.1038/nrcardio.2015.92.